Nanexa AB (publ) (STO:NANEXA)

Sweden · Delayed Price · Currency is SEK

3.810

-0.175 (-4.39%)

Mar 2, 2026, 5:24 PM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Drug Delivery Systems	55.94M	46.69M	59.16M	27.17M	18.01M
Drug Delivery Systems Growth	19.80%	-21.07%	117.72%	50.87%	-13.66%
Total	55.94M	46.69M	59.16M	27.17M	18.01M
Total Growth	19.80%	-21.07%	117.72%	50.87%	-13.66%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Nordic Countries	18.37M	25.25M	1.01M	248.00K
Nordic Countries Growth	-27.23%	2392.30%	308.47%	77.14%
Europe (Excluding The Nordic Countries)	1.32M	-	-	304.00K
Europe (Excluding The Nordic Countries) Growth	-	-	-	61.70%
North America	4.67M	4.01M	1.85M	1.82M
North America Growth	16.38%	117.11%	1.37%	-10.64%
Asia	-	70.00K	-	-
Total	24.36M	29.33M	2.86M	2.37M
Total Growth	-16.93%	925.42%	20.47%	0.30%

Source: S&P Global Market Intelligence.